Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Account Payables (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Account Payables for 4 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 934.69% to -$2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $471000.0, a 31.34% decrease, with the full-year FY2025 number at $471000.0, down 31.34% from a year prior.
  • Change in Account Payables was -$2.0 million for Q4 2025 at Day One Biopharmaceuticals, down from $688000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.4 million in Q1 2023 to a low of -$3.7 million in Q4 2022.
  • A 4-year average of $124312.5 and a median of -$168000.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: soared 2348.65% in 2024, then crashed 934.69% in 2025.
  • Day One Biopharmaceuticals' Change in Account Payables stood at -$3.7 million in 2022, then skyrocketed by 78.05% to -$815000.0 in 2023, then surged by 130.06% to $245000.0 in 2024, then plummeted by 934.69% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Change in Account Payables are -$2.0 million (Q4 2025), $688000.0 (Q3 2025), and $2.6 million (Q2 2025).